English Swedish
Published: 2022-02-16 07:30:00 CET
Surgical Science Sweden AB
Interim information

Year-end report 2021: STRONG END TO A TRANSFORMATIVE YEAR

FOURTH QUARTER 2021 (OCT – DEC)

Net sales amounted to SEK 197.7 million (39.6), corresponding to an increase of 399 percent compared with the corresponding period in the preceding year. Fourth quarter sales included an item of SEK 9.5 million attributable to the adjustment of accounting principles regarding the period in which certain income is reported.

Simbionix and Mimic are included in the amount of SEK 138.7 million combined. For comparable units, sales increased by 31 percent.

Operating profit amounted to SEK 44.5 million (12.6).

Net profit amounted to SEK 66.9 million (10.6), corresponding to earnings per share of SEK 1.32 (0.31).

Cash flow from operating activities amounted to a net outflow of SEK 13.0 million (inflow 16.7). As of December 31, 2021, cash and cash equivalents amounted to SEK 316.7 million (87.2).

FULL-YEAR 2021

Net sales amounted to SEK 366.8 million (104.8), corresponding to an increase of 250 percent compared with the preceding year.

For comparable units, sales increased by 34 percent.

Pro forma, the Group’s sales for 2021 amounted to SEK 597.0 million (500.9), an increase of 19 percent.

Operating profit amounted to SEK 56.5 million (20.0). The outcome includes acquisition costs of SEK 28.5 million.

Net profit amounted to SEK 86.2 million (15.6), corresponding to earnings per share of SEK 2.03 (0.45).

Cash flow from operating activities amounted to SEK 39.1 million (23.2).

In January, Mimic Technologies was acquired, with operations in robotic surgery. The transfer of ownership took place on January 27.

In August, Simbionix was acquired, further strengthening Surgical Science’s position in simulation for robotic surgery and broadening the operations with new application areas. The transfer of ownership took place on August 24.

Gothenburg, Sweden, February 16, 2022
Surgical Science Sweden AB (publ)

This report, in its entirety, is available through the attachment or via:
https://surgicalscience.com/aktien/pressmeddelanden/
https://surgicalscience.com/aktien/finansiella-rapporter/

This is a translation of the Swedish version of the interim report. When in doubt, the Swedish wording prevails.

For further information, please contact:

Gisli Hennermark, CEO
Telephone: +46-70-420 83 00
E-mail: gisli.hennermark@surgicalscience.com

Anna Ahlberg, CFO
Telephone: +46-70-855 38 35
E-mail: anna.ahlberg@surgicalscience.com

About Surgical Science Sweden AB (publ)

One of the biggest challenges within healthcare globally is how injuries during care can be reduced. Medical education and training are key, as a large part of the training today can be performed outside the operating room. Surgical Science is a world leader in the manufacture of virtual reality simulators for evidence-based training. The simulators enable surgeons and other medical specialists to train and improve their psychomotor skills and instrument handling before entering the operating room. In parallel with its own products, Surgical Science works with simulation solutions for medical technology companies that develop surgical instruments for clinical use, such as robotic surgery.

Surgical Science has more than 200 employees. The company is headquartered in Gothenburg, Sweden and also has operations in Stockholm, Sweden, as well as in Tel Aviv, Israel and Seattle, US. Through sales offices in the US, France and China as well as a global network of distributors, Surgical Science maintains a presence in most markets. Surgical Science Sweden AB (publ) is traded on Nasdaq First North Growth Market. Certified Adviser is Erik Penser Bank (Phone: +46 8-463 83 00; E-mail: certifiedadviser@penser.se).

This information is information that Surgical Science Sweden AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2022-02-16 07:30 CET.


220216 Q42021 ENG.pdf
This news release was distributed by Company News System, www.nasdaqomxnordic.com/news/marketnotices
To subscribe on regulatory news from this company, go to the subscription page